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Albuminuria in diabetic nephropathy is due to endothelial
dysfunction, a loss of negative charges in the basement
membrane, and changes a of the slit-membrane diaphragm
composition. We have recently shown that protein kinase C
alpha (PKCa)-deficient mice are protected against the
development of albuminuria under diabetic conditions.
We here tested the hypothesis that PKCa mediates the
hyperglycemia-induced downregulation of the
slit-diaphragm protein nephrin. After 8 weeks of
streptozotocin (STZ)-induced hyperglycemia the expression
of glomerular nephrin was significantly reduced. In contrast,
other slit-diaphragm proteins such as podocin and CD2AP
were unaltered in diabetic state. In PKCa/ mice,
hyperglycemia-induced downregulation of nephrin was
prevented. Podocin and CD2AP remained unchanged. In
addition, the nephrin messenger RNA expression was also
reduced in hyperglycemic wild-type mice but remained
unaltered in PKCa/ mice. We postulate that the underlying
mechanism of the hyperglycemia-induced regulation of
various proteins of the glomerular filtration barrier is a
PKCa-dependent regulation of the Wilms’ Tumor Suppressor
(WT1) which previously has been shown to act as a direct
transcription factor on the nephrin promoter. Our data
suggest that PKCa activation may be an important
intracellular signaling pathway in the regulation of nephrin
expression and glomerular albumin permeability in the
diabetic state.
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The incidence of diabetes mellitus is steadily rising and
diabetic nephropathy is the leading cause of end-stage renal
disease. An early marker for diabetic nephropathy is the
occurrence of microalbuminuria. The glomerular vasculature
consists of three structures that act in concert to prevent the
development of albuminuria and proteinuria. These struc-
tures are the fenestrated endothelium, the glomerular base-
ment membrane and the epithelial slit diaphragm. Several
authors have shown that hyperglycemia leads to a down-
regulation of negatively charged proteoglycans in the base-
ment membrane of the glomerulus.1 Recently, a role of the
slit membrane and especially of nephrin in the pathogenesis
of diabetic albuminuria has been suggested.2 An open
question is which signaling pathways are involved in
mediating the effects of hyperglycemia on the basement
membrane and the slit-membrane proteins.3
We have recently demonstrated that protein kinase C
alpha (PKCa)/ animals are protected against the develop-
ment of albuminuria.4 When we analyzed the basement
membrane in the PKCa-deficient diabetic mice we found that
the loss of the negatively charged heparan sulfate proteo-
glycans was almost completely prevented and the glomerular
basement membrane only modestly affected by hyperglyce-
mia. Furthermore we were able to demonstrate, that PKCa
influence the vascular endothelial growth factor system,
which could contribute to an increased endothelial perme-
ability. These findings suggest that PKCa is a major
intracellular mediator of hyperglycemia – induced changes
in the basement membrane. However, the second molecular
system regulating glomerular permeability, that is, slit-
diaphragm proteins has not been analyzed so far.
We therefore tested the hypothesis that PKCa mediates
the hyperglycemia-induced downregulation of the slit-
diaphragm protein nephrin because several groups
previously demonstrated that nephrin expression is reduced
in diabetic animals with albuminuria.5–7 Furthermore, similar
data were obtained in human when kidney biopsies from
patients with Type I as well as Type II diabetes mellitus
were studied.8–12
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RESULTS
Hyperglycemia was induced in 7-week-old mice by intra-
peritoneal injection of streptozotocin (STZ) on day 1 and 4.
After 8 weeks of hyperglycemia the nonfasting blood glucose
levels were 25.973.4 mmol/l in the diabetic wild-type (WT)
(n¼ 6) and 32.271.6 mmol/l in the PKCa/ mice (n¼ 7).
In the sham-injected mice the levels were 12.270.9 mmol/l in
WT (n¼ 7) and 10.970.6 mmol/l in the PKCa/ mice
(n¼ 7).
After 8 weeks of hyperglycemia a significant higher
urinary albumin excretion was detected in WT diabetic mice
(24.7878.98 g/mol creatinine) compared with WT control
mice (7.3770.47 g/mol creatinine) (Po0.05). Notably, no
significant increase of the albumin/creatinine ratio was
observed in the diabetic PKCa/ (9.8871.67 g/mol creati-
nine) in comparison to control PKCa/ mice (6.9471.81 g/
mol creatinine).
To further reveal the mechanism responsible for the
prevention in albuminuria in the diabetic PKCa/ animals,
we studied the expression of nephrin, a key protein of the
glomerular slit membrane. We first assessed the expression of
nephrin by immunochemistry. As shown in Figure 1 there
was a strong podocytary expression of nephrin in the
glomerular of nondiabetic WT (A) and PKCa/ mice (C).
Notably, the glomerular expression of nephrin was signifi-
cantly reduced in the diabetic WT animals and was barely
detectable (Figure 1b). Importantly, this diabetes-induced
loss of glomerular nephrin expression was completely
prevented in the diabetic PKCa/ mice (Figure 1d).
To evaluate the role of other slit-diaphragm proteins, we
secondly performed tissue analysis of other slit-diaphragm
proteins, podocin and CD2AP. Podocin showed a podocytary
expression comparable to nephrin in nondiabetic WT mice
(Figure 2a). However, in contrast to nephrin, hyperglycemia
did not induce any change in the expression level of podocin
in the diabetic WT (Figure 2b). We also did not observe any
changes in the nondiabetic (Figure 2c) and diabetic PKCa/
mice (Figure 2d). Immunohistochemistry of the third slit-
diaphragm protein, CD2AP, displayed comparable results to
podocin as shown in (Figure 3a–d). Hyperglycemia did not
have any effect on the expression of CD2AP in WT and
PKCa/ mice.
As we observed a prevention of the hyperglycemia-
induced nephrin loss in our diabetic PKCa/ mice, we next
measured the nephrin expression by western blot analysis as
well as the podocin and CD2AP expression to confirm and
quantitatively analyze the results obtained from the im-
munohistological tissue evaluation. The results are shown in
Figure 4a–c. Nephrin was expressed as a single band with a
molecular weight (MW) of 136 kDa. Hyperglycemia of 8
weeks reduced the expression of nephrin significantly as
observed with immunohistochemical analysis. The high-
glucose-induced nephrin loss is again prevented in the
PKCa/ mice (Figure 4a). In contrast, Western blot analysis
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Figure 1 | Immunohistochemistry of nephrin expression in WT
and PKCa/ mice. Immunohistochemistry of nephrin expression
in (a, b) WT and (c, d) PKCa/ mice shows markedly reduced
expression of nephrin in (b) diabetic WT mice compared to the other
groups. Paraffin sections; bar¼ 50mm. (b) hyperglycemia-induced
nephrin loss is prevented in the diabetic PKCa/ mice.
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Figure 2 | Immunohistochemistry of podocin expression in WT
and PKCa/ mice. Immunohistochemistry of podocin expression in
(a, b) WT and (c, d) PKCa/ mice displays no hyperglycemia-induced
change in the expression of podocin in the diabetic WT animals
compared to healthy controls. Furthermore, WT and PKCa/
mice shows comparable expression levels. Paraffin sections;
bar¼ 50 mm.
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of podocin (MW 42 kDa) (Figure 4b) and CD2AP (MW
80 kDa) (Figure 4C) expression did not show any difference
in both diabetic, WT and PKCa/, groups. These results
again confirm our previous immunohistochemical data. To
further substitute our findings that PKCa prevents the
hyperglycemia-induced downregulation of nephrin, we also
quantitatively analyzed nephrin messenger RNA (mRNA)
expression using real-time polymerase chain reaction. These
results are presented in Figure 5. The graph displays again the
significant downregulation of nephrin mRNA expression and
its prevention in the diabetic PKCa/ mice (Figure 5)
indicating a role of PKCa on the transcriptional level of
nephrin expression.
To further study the molecular mechanism involved in the
observed PKCa – mediated prevention of the hyperglycemia-
induced downregulation of nephrin, we then performed
immunochemistry of the Wilms’ Tumor Suppressor (WT1)
which previously has been shown to act as a direct
transcription factor on the nephrin promoter.13,14 Figure 6a
displays decreased expression level of WT1 in diabetic WT
animals compared to both nondiabetic controls, WT and
PKCa/ mice. Interestingly, diabetic PKCa/ mice are
protected against the loss of WT1 which is also shown in the
semiquantitative analysis displayed in Figure 6b. These results
suggest that hyperglycemia-induced regulation of nephrin
expression is regulated on the transcriptional level via a
PKCa-induced downregulation of the transcription factor
WT1 of the nephrin promoter.
DISCUSSION
In the present study we confirmed our previous observation
that PKCa is an important mediator of hyperglycemia-
induced glomerular damage leading to albuminuria. We now
demonstrated that PKCa is directly responsible for the loss
of nephrin in STZ-induced diabetes mellitus. The other
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Figure 3 | Immunohistochemistry of CD2AP expression in WT and
PKCa/ mice. Immunohistochemistry of CD2AP expression in
(a, b) WT and (c, d) PKCa/ mice shows no difference between
nondiabetic and diabetic animals as well as WT and PKCa/ mice.
Paraffin sections; bar¼ 50 mm.
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Figure 4 | Western-blot analysis of slit-diaphragm proteins.
Western-blot analysis of (a) nephrin, (b) podocin, and (c) CD2AP
protein expression. The picture displays a representative blot from
the four different study groups regarding all three slit-diaphragm
proteins. (a) In WT diabetic animals the nephrin protein amount (MW
136 kDa) is reduced to a third of the values detectable in WT control
mice (*Po0.05) whereas no reduction of the nephrin content is
observed in the diabetic PKCa/ mice. (b,c) Podocin (MW 42 kDa)
and CD2AP (MW 80 kDa) levels remain again constantly unchanged.
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slit-diaphragm proteins, podocin and CD2AP, were not
downregulated in diabetic mouse kidney tissue. Interestingly,
a similar expression pattern of these three slit-diaphragm
proteins has been described in human kidney biopsies. The
hyperglycemia-induced transcriptional downregulation of
nephrin is regulated via a PKCa-induced downregulation of
the transcription factor WT1, which has a binding site in the
nephrin promoter. Our findings underscore a pathophysio-
logic role of PKCa in the development of diabetic kidney
disease.
The role of the various PKC isoforms has been widely
studied in the previous years.15,16 PKCb has been postulated
to be the most important PKC isoform activated in the
diabetic state and several in-vitro and in-vivo studies, mainly
using an pharmacological approach with the PKCb-selective
inhibitor Ruboxistaurin (LY333531), have shown beneficial
effects on the development of various diabetic microvascular
complications.3,17 In contrast, several other authors have
related increased activation of PKCe, a novel, calcium-
independent isoform, to glomerular and tubular changes in
the diabetic millieu.18–20 It has been suggested that high-
glucose-induced increase in PKCe- and PKCd-content and
translocation in cultured mesangial cells mediates protein-
uria, possibly through increased oxidative stress mediating
enhanced cell signaling responsiveness to vasoactive peptides
in diabetes mellitus.16,18–20 Furthermore, another classical
isoform, PKCa, has been proposed to exert a central role in
the development of diabetic microvascular complications and
insulin signaling.21,22 Recently, we investigated diabetic rats
using the STZ-induced diabetes model and found that PKCa
is markedly increased in glomeruli and interstitial capillaries
as well as in the endothelial cells of larger arteries.23 Our
present results now suggest a central role of PKCa in the
development of early diabetic nephropathy and proteinuria.
However, the divergent results for other PKC isoforms may
be due to different tissue and cell specificity of the various
PKC isoforms not only in the diabetic state.15,16,24
Possible mechanisms involved in the development of
albuminuria are (1) downregulation of slit-diaphragm
protein and/or mRNA expression with subsequent structural
disturbance and (2) changes in the glomerular basement
membrane composition with loss of the negatively charged
heparan sulfate proteoglycans.4 It is well known, that
albuminuria is diminished by administration of angio-
tensin-converting enzyme inhibitors or angiotensin II
receptor blockers.25 Both compounds are able to increase
the nephrin production in diabetic animals5,12,26 suggesting
that angiotensin II inhibits nephrin production. Further-
more, advanced glycation endproducts have also been
implicated to play a role in the downregulation of nephrin
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Figure 5 | Real-time polymerase chain reaction of nephrin mRNA
expression. We found a significant reduction of nephrin mRNA levels
in whole-kidney extracts from diabetic vs control WT mice (*Po0.05).
In contrast, no reduction of nephrin mRNA levels was observed in
diabetic PKCa/ mice (n¼ 3 per group).
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Figure 6 | Immunohistochemistry of WT1 expression in WT and
PKCa/ mice. (a) The original picture in displays a significant
decrease in the WT diabetic mice whereas the diabetic PKCa/ mice
are protected against the loss of WT1 as previously shown for nephrin
expression. (b) Semiquantitative analysis of the expression profile is
shown in figure. Paraffin sections; bar¼ 50mm; *Po0.05.
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in diabetic rodents. Indeed, it has been demonstrated that
administration of the advanced glycation endproducts
inhibitor aminoguanidine ameliorated the diabetes-induced
nephrin protein depletion.24 Notably, it also has been shown
that angiotensin-converting enzyme inhibitors and angio-
tensin II blockers as well as aminoguanidine or the novel
advanced glycation endproducts-crosslink-breaker ALT711
reduce PKC activity.27,28 Therefore, we assume that the
beneficial effect of the above mentioned compounds on
albuminuria is at least partially explained by a reduction of
the PKCa isoform activity.
Nephrin, a member of the immunoglobulin superfamily,
has been recently proven to be an integral membrane protein
of the slit diaphragm mutated in the congentinal nephritic
syndrome of the Finnish type 1.29 Other studies have
outlined the role of nephrin loss in the development of
diabetic nephropathy.5–12 It has been suggested that one of
the 12 PKC isoforms may be the key intracellular signaling
system in the regulation of nephrin mRNA and protein
expression 30.30 Several authors have shown that nephrin is
regulated on a transcriptional level. The regulatory elements
of the nephrin promoter are located within a region of 5.4 kb
upstream from the nephrin gene.31–33 Recently, two separate
studies have nicely demonstrated that the WT1 acts as a
direct transcription factor on the nephrin promoter.13,14 Our
data add to this observation that PKCa signaling is an
important regulator of this transcriptional activator of the
nephrin promoter. If the effect of PKCa is mediated by direct
phosphorylation of WT1 or indirectly by regulation of other
signal-transduction molecules will be studied in the future.
Podocin, a stomatin family member, is another important
component of the glomerular slit-diaphragm complex which
colocalizes and interacts with nephrin and CD2AP in the
lipid rafts of the podocyte foot process cell membrane.34
Podocin is mutated in the nephritic syndrome of the Finnish
type 2 and is associated with the familial steroid-resistant
nephrotic syndrome manifest as early childhood onset of
proteinuria, rapid progression to end-stage renal disease, and
focal segmental glomerulosclerosis suggesting a regulatory
role for podocin in determining glomerular permeability.34
However, Benigni et al.9 revealed that in human renal
biopsies podocin and CD2AP expression is unaltered in
individuals with diabetic nephropathy. Our results confirm
these results in the STZ-induced diabetic mouse model.
Deletion of CD2AP, an adaptor protein expressed in
glomerular podocytes, also leads to experimental congenital
nephritic syndrome suggesting its important role in the
structural integrity of the glomerular slit diaphragm.35 As
CD2AP has recently been shown to directly interact with
nephrin in vitro and in vivo, it may serve as an adaptor
protein mediating the interaction of podocin and nephrin.36
Our results confirm that depletion of nephrin, but not
podocin or CD2AP, is mainly induced by hyperglycemia and
at least partly responsible for proteinuria in diabetes mellitus.
Notably, these data suggest that this important effect of
hyperglycemia is mediated by the PKCa isoform.
We recently demonstrated that PKCa mediates diminished
expression of the basal membrane proteoglycans such as
perlecan.4 Together with the results of the present study our
findings support the hypothesis that two distinct mechanisms
of diabetes-induced proteinuria, the loss of negative charge in
the basal membrane and the loss of the specific slit-
diaphragm protein nephrin, are mediated by PKCa. Whether
this is a direct stimulatory effect of PKCa or if other
intracellular pathways are involved in this process has to be
ruled out in future studies.
In summary, we demonstrate in the present study that the
PKCa isoform is a negative regulator of nephrin mRNA
expression under diabetic conditions. This effect is regulated
through a PKCa-dependent downregulation of the transcrip-
tion factor WT1 of the nephrin promoter. The loss of
nephrin mRNA expression and nephrin protein production
observed in diabetic WT animals is completely prevented in
mice that do not express PKCa. We therefore suggest that an
increased PKCa activity is of pivotal importance for the
development of albuminuria in diabetes mellitus.
MATERIALS AND METHODS
Animal model
Experiments were performed with male 129/SV PKCa/ mice37
and 129/SV WT animals from the strain that was used to generate
the 129/SV PKCa/ mice. A subset of the animals analyzed
previously, were used for the present study.4
The animals received a standard diet with free access to tap water.
All procedures were carried out according to guidelines from the
American Physiological Society and were approved by local
authorities. Eight-week-old weight-matched mice received either
50 mg/kg body weight STZ (Sigma-Aldrich, Munich, Germany) in
50 mM sodium citrate (pH 4.5) or sodium citrate buffer intraper-
itoneally on 5 consecutive days. Blood glucose measurement was
performed from tail blood using the glucometer Elite (Bayers,
Leverkusen, Germany) every other day. Animals with glucose levels
above 15 mmol/l on two consecutive measurements were regarded as
hyperglycemic and glucose measurements were extended to once
weekly. Animals, which had no hyperglycemia 20 days after the last
STZ injection, were not used for our experiments. The mice received
no insulin within the complete study period. Ketonuria did not
occur (data not shown). After 8 weeks of hyperglycemia the animals
were killed according to a standardized protocol as previously
published.4 Briefly, after anesthesia with Avertin (2.5%) a lapar-
otomy was performed and urine was collected by puncturing the
bladder with a 23-gauge needle. Then, the abdominal aorta was
cannulated again with a 23-gauge needle and the organs were
perfused with lactated Ringer solution. After ligation of the left renal
artery, the left kidney was removed, weighed, and snap-frozen in
isopentane (401C). Afterwards, the right kidney was perfused with
3% paraformaldehyde in 0.1 M Soerensen’s phosphate buffer. The
right kidney was fixed for an additional 20 h in 3% paraformalde-
hyde in Soerensen’s phosphate buffer and then paraffin embedded.
Immunohistochemistry
Immunohistochemistry was performed as described recently.4 For
these studies following rabbit polyclonal antibodies were
used: rabbit anti-nephrin which was kindly provided by Dr
Holthoefer from University of Helsinki,38 rabbit anti-CD2AP, rabbit
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anti-podocin, and rabbit anti-WT-1 (all from Santa Cruz Biotech-
nology, Santa Cruz, CA, USA). For indirect immunofluorescence
nonspecific binding sites were blocked with 10% normal donkey
serum (Jackson ImmunoResearch Lab, West Grove, PA, USA) for
30 min. Then sections were incubated with the primary antibody for
1 h. For fluorescent visualization of bound primary antibodies,
sections were further incubated with Cy3-conjugated secondary
antibodies (Jackson ImmunoResearch Lab, West Grove, PA, USA)
for 1 h. Specimens were analyzed using a Zeiss Axioplan-2 imaging
microscope with the computer program AxioVision 4.3 (Zeiss, Jena,
Germany).
Protein chemistry
Western blotting was performed as described recently.4 The frozen
kidneys were pulverized in liquid nitrogen and resuspended in 2 ml
of lysis buffer (20 mmol/l Tris buffer (pH 7.5) containing 10 mmol/l
glycerophosphate, 2 mmol/l pyrophosphate, 1 mmol/l sodium
fluoride, 1 mmol/l phenylmethylsulfonyl fluoride, 1 g/ml leupeptin,
1 mmol/l dithiothreitol, and 1 mmol/l ethylenediaminetetraacetic
acid). Homogenates were sonicated for three 20-s bursts on ice and
centrifuged at 500 g for 1 min to remove cell debris. Aliquots of the
supernatants were stored at 801C. The protein amount was
measured using the Lowry assay. A total of 30 mg of protein of each
sample was resuspended in loading buffer and run on a 10%
polyacrylamide gel and electrophoretically transferred to nitrocellu-
lose membrane. Primary antibodies against nephrin, podocin and
CD2AP were applied with gentle rocking overnight at 41C. After
three 10-min washing steps with Tris-bufered saline/0.2% Tween 20
buffer (50 mmol/L Tris HCl, pH 7.5, 150 mmol/l NaCl, 0.01% Tween
20), incubation with horseradish peroxidase conjugated goat-anti-
rabbit secondary antibody (Dianova, Hamburg, Germany) was
performed for 1 h at room temperature. After three further Tris-
bufered saline/0.2% Tween 20 washes, the membrane was incubated
with Renaissance reagent (NEN Life Science, Zaventem, Belgium)
according to the manufacturer’s instructions and exposed to X-ray
film (Kodak, Stuttgart, Germany). Quantification was done by
measuring relative density and normalized for actin (Scion Image,
Frederich, MD, USA).
Taqman polymerase chain reaction
Real-time quantitative polymerase chain reaction was performed as
described earlier.4 Primers were designed using Primer Express
software (Applied Biosystems, Germany) based on Unigene clusters
or GenBank accession numbers, respectively (given in parenthesis).
The primer sequences are the following (50-30-direction): r18S
(NC_001665) ACATCCAAGGAAGGCAGCAG (Primer 1) and TTTTC
GTCACTACCTCCCCG (Primer 2) and for nephrin (NM_019459)
ACTACGCCCTCTTCAAATGCA (Primer 1) and TCGAGGGCCT
CATACCTGAT (Primer 2).
Statistics
Data are shown as mean7s.e.m. The data were compared by
analysis of variance with appropriate post-test. Data analysis was
performed using InStat.
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